Pricing

  For pricing information, USA customers sign in.
  Outside USA? Please contact your distributor for pricing.

Specifications

Ponatinib is a novel potent, orally available small molecule multitargeted kinase inhibitor. Ponatinib inhibits both native and mutant BCR-ABL. Ponatinib is used in the treatment of chronic myeloid leukemia (CML) with BCR-ABL kinase inhibitors.
Catalog #	019859
Melting Point	As reported
Solubility	As reported
Method for Determining Identity	Proton NMR (DMSO-d6) Spectroscopic and Mass Spectrometric Analysis
TLC Conditions	As reported
Storage and Stability	May be stored at RT for short-term only. Long-term storage is recommended at 4°C. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Light sensitive. Store under inert atmosphere.
Important Note	This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Toxicity and Hazards
	All products should be handled by qualified personnel only, trained in laboratory procedures.
CAS Number	943319-70-8
Molecular Formula	C29H27F3N6O
Molecular Weight	532.56
Purity	~90% by HPLC
Form	As Reported
Alternate names	3-(2-Imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]benzamide; AP 24534;